FULC

SEC source: 0000899243-21-026555 · doc4.xml · nonDerivative · entry 1

Thomson Peter G. · CIK 0001779120 · VP Finance & Accounting

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,300

F1 · ownership.nature: Held by the Reporting Person's child.

SEC source: 0000899243-21-026552 · doc4.xml · nonDerivative · entry 1

GERAGHTY JAMES A · CIK 0001239746 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,714

SEC source: 0000899243-21-026557 · doc4.xml · nonDerivative · entry 1

Morabito Christopher · CIK 0001859284 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,100

SEC source: 0000899243-21-026556 · doc4.xml · nonDerivative · entry 1

Oltmans Curtis Gale · CIK 0001714982 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,088

SEC source: 0000899243-21-023287 · doc4.xml · derivative · entry 1

LEVIN MARK J · CIK 0001180428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-08

F1 · derivative.exercise_date: This option was granted on June 9, 2021 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0000899243-21-023288 · doc4.xml · derivative · entry 1

Collins James J. · CIK 0001779269 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-08

F1 · derivative.exercise_date: This option was granted on June 9, 2021 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0000899243-21-023285 · doc4.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-08

F1 · derivative.exercise_date: This option was granted on June 9, 2021 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0000899243-21-023286 · doc4.xml · derivative · entry 1

GERAGHTY JAMES A · CIK 0001239746 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-08

F1 · derivative.exercise_date: This option was granted on June 9, 2021 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0000899243-21-023282 · doc4.xml · derivative · entry 1

Dorton Katina · CIK 0001617541 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-08

F1 · derivative.exercise_date: This option was granted on June 9, 2021 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0000899243-21-023283 · doc4.xml · derivative · entry 1

Haviland Kate · CIK 0001663022 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-08

F1 · derivative.exercise_date: This option was granted on June 9, 2021 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0000899243-21-019264 · doc4.xml · derivative · entry 1

Morabito Christopher · CIK 0001859284 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,000

Underlying: Common Stock · 163,000 shares

Expires 2031-05-09

F1 · derivative.exercise_date: This option was granted on May 10, 2021 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of May 10, 2021. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service.

SEC source: 0000899243-21-014591 · doc4.xml · derivative · entry 1

Dunn Judith · CIK 0001811904 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,000

Underlying: Common Stock · 215,000 shares

Expires 2031-03-31

F1 · derivative.exercise_date: This option was granted on April 1, 2021 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of April 1, 2021. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service.

SEC source: 0000899243-21-014592 · doc4.xml · derivative · entry 1

Stuart Bryan · CIK 0001619846 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2031-03-30

F1 · derivative.exercise_date: This option was granted on March 31, 2021 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of March 31, 2021, subject to continued service.

SEC source: 0000899243-21-012179 · doc4.xml · nonDerivative · entry 2

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 506,630

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.01 to $12.85, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0000899243-21-012179 · doc4.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 507,419

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.51, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0000899243-21-008015 · doc4.xml · derivative · entry 3

Thomson Peter G. · CIK 0001779120 · VP Finance & Accounting

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,471

Underlying: Common Stock · 5,000 shares

Expires 2029-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020.

F3 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2019, subject to continued service.

SEC source: 0000899243-21-008015 · doc4.xml · nonDerivative · entry 2

Thomson Peter G. · CIK 0001779120 · VP Finance & Accounting

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,212

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.31 to $15.03, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0000899243-21-008015 · doc4.xml · nonDerivative · entry 1

Thomson Peter G. · CIK 0001779120 · VP Finance & Accounting

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,212

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020.

SEC source: 0000899243-21-007119 · doc4.xml · nonDerivative · entry 2

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 516,630

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.48 to $14.88, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0000899243-21-007119 · doc4.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 518,303

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.48 to $14.47, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0000899243-21-005666 · doc4.xml · derivative · entry 1

Moxham Christopher · CIK 0001843784 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2031-02-07

F1 · derivative.exercise_date: This option was granted on February 8, 2021 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of February 6, 2021, subject to continued service.

SEC source: 0000899243-21-004949 · doc4.xml · derivative · entry 1

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 269,390

Underlying: Common Stock · 269,390 shares

Expires 2031-02-01

F1 · derivative.exercise_date: This option was granted on February 2, 2021 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2021, subject to continued service.

SEC source: 0000899243-21-003472 · doc4.xml · derivative · entry 1

Thomson Peter G. · CIK 0001779120 · VP Finance & Accounting

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2031-01-24

F1 · derivative.exercise_date: This option was granted on January 25, 2021 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2021, subject to continued service.

SEC source: 0000899243-21-003474 · doc4.xml · derivative · entry 1

Stuart Bryan · CIK 0001619846 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,376

Underlying: Common Stock · 134,376 shares

Expires 2031-01-24

F1 · derivative.exercise_date: This option was granted on January 25, 2021 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2021, subject to continued service.

SEC source: 0000899243-21-003173 · doc4.xml · nonDerivative · entry 1

Thomson Peter G. · CIK 0001779120 · VP Finance & Accounting

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,212

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020.

F2 · balance_after: Includes 748 shares acquired under the Issuer's employee stock purchase plan on November 13, 2020.

SEC source: 0000899243-21-002928 · doc4.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 524,845

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.365, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0000899243-20-032868 · doc4.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-12-02

F1 · derivative.exercise_date: This option was granted on December 3, 2020 and is scheduled to vest with respect to all shares on November 2, 2021, subject to continued service.

SEC source: 0000899243-20-032867 · doc4.xml · derivative · entry 1

Oltmans Curtis Gale · CIK 0001714982 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,600

Underlying: Common Stock · 153,600 shares

Expires 2030-12-02

F1 · derivative.exercise_date: This option was granted on December 3, 2020 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of November 30, 2020. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service.

SEC source: 0000899243-20-024982 · doc4.xml · derivative · entry 2

Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,592

Underlying: Common Stock · 6,350 shares

Expires 2029-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022.

SEC source: 0000899243-20-024982 · doc4.xml · nonDerivative · entry 1

Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,438

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-20-018815 · doc4.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 534,845

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019.

SEC source: 0000899243-20-018817 · doc4.xml · derivative · entry 3

Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,942

Underlying: Common Stock · 2,951 shares

Expires 2029-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019.

F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022.

SEC source: 0000899243-20-018817 · doc4.xml · nonDerivative · entry 2

Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,088

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019.

SEC source: 0000899243-20-018817 · doc4.xml · nonDerivative · entry 1

Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,039

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019.

SEC source: 0000899243-20-018278 · doc4.xml · nonDerivative · entry 1

Cadavid Diego · CIK 0001778713 · SVP Clinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,714

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019.

SEC source: 0000899243-20-018121 · doc4.xml · derivative · entry 3

Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,893

Underlying: Common Stock · 141 shares

Expires 2029-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019.

F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022.

SEC source: 0000899243-20-018121 · doc4.xml · nonDerivative · entry 2

Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,088

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019.

SEC source: 0000899243-20-018121 · doc4.xml · nonDerivative · entry 1

Wallace Owen B. · CIK 0001778843 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,229

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019.

SEC source: 0000899243-20-017758 · doc4.xml · nonDerivative · entry 1

Gould Robert J · CIK 0001577034 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 537,345

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.32 to $21.26, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0000899243-20-017761 · doc4.xml · derivative · entry 3

Cadavid Diego · CIK 0001778713 · SVP Clinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,277

Underlying: Common Stock · 1,459 shares

Expires 2028-07-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019.

F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022.

SEC source: 0000899243-20-017761 · doc4.xml · nonDerivative · entry 2

Cadavid Diego · CIK 0001778713 · SVP Clinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,785

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019.

SEC source: 0000899243-20-017761 · doc4.xml · nonDerivative · entry 1

Cadavid Diego · CIK 0001778713 · SVP Clinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,244

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019.

SEC source: 0000899243-20-016500 · doc4.xml · derivative · entry 1

LEVIN MARK J · CIK 0001180428 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,285

Underlying: Common Stock · 9,285 shares

Expires 2030-06-10

F1 · derivative.exercise_date: This option was granted on June 11, 2020 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0000899243-20-016497 · doc4.xml · derivative · entry 1

Collins James J. · CIK 0001779269 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,285

Underlying: Common Stock · 9,285 shares

Expires 2030-06-10

F1 · derivative.exercise_date: This option was granted on June 11, 2020 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0000899243-20-016498 · doc4.xml · derivative · entry 1

Ezekowitz Alan · CIK 0001780209 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,285

Underlying: Common Stock · 9,285 shares

Expires 2030-06-10

F1 · derivative.exercise_date: This option was granted on June 11, 2020 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0000899243-20-016499 · doc4.xml · derivative · entry 1

GERAGHTY JAMES A · CIK 0001239746 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,285

Underlying: Common Stock · 9,285 shares

Expires 2030-06-10

F1 · derivative.exercise_date: This option was granted on June 11, 2020 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0000899243-20-016496 · doc4.xml · derivative · entry 1

Haviland Kate · CIK 0001663022 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,285

Underlying: Common Stock · 9,285 shares

Expires 2030-06-10

F1 · derivative.exercise_date: This option was granted on June 11, 2020 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

SEC source: 0000899243-20-016382 · doc4.xml · derivative · entry 3

Cadavid Diego · CIK 0001778713 · SVP Clinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,736

Underlying: Common Stock · 401 shares

Expires 2028-07-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019.

F2 · derivative.exercise_date: The shares underlying the option are scheduled to vest in equal quarterly installments from July 16, 2018 through July 15, 2022.

SEC source: 0000899243-20-016382 · doc4.xml · nonDerivative · entry 2

Cadavid Diego · CIK 0001778713 · SVP Clinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,785

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019.

SEC source: 0000899243-20-016382 · doc4.xml · nonDerivative · entry 1

Cadavid Diego · CIK 0001778713 · SVP Clinical Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,186

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019.